Chk2 k472 site-modified polypeptides, specific antibodies and uses thereof

By preparing a CHK2 K472 site-modified peptide and obtaining a polyclonal antibody, the shortcomings of existing CHK2-specific antibodies are overcome, and efficient recognition of CHK2 crotonylation modification is achieved, which can be used to monitor CHK2 protein changes and develop tumor-targeted drugs.

CN123063372APending Publication Date: 2026-11-10PEKING UNIV CANCER HOSPITAL INNER MONGOLIA HOSPITAL (AFFILIATED CANCER HOSPITAL OF INNER MONGOLIA MEDICAL UNIV INNER MONGOLIA AUTONOMOUS REGION CANCER HOSPITAL INNER MONGOLIA AUTONOMOUS REGION CANCER CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611471518.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-21
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies struggle to provide highly efficient CHK2-specific antibodies for capturing and regulating CHK2 function, elucidating DNA damage repair, and exploring new mechanisms of tumor development and progression. Direct tools for targeted drug development are also lacking.

Method used

A CHK2 K472 site-modified peptide was prepared, and polyclonal antibodies were obtained by immunizing animals. The crotonylation modification of the CHK2 K472 site was specifically recognized, and the peptide was purified by protein A affinity chromatography and antigen peptide affinity chromatography to obtain highly efficient polyclonal antibodies Anti-Crotonyl CHK2 (K472)-1415R311 and Anti-Crotonyl CHK2 (K472)-1415R411.

Benefits of technology

It provides a highly efficient CHK2 K472 site-specific antibody that can specifically recognize and track CHK2 crotonylation modification in complex mixtures of cellular proteins, and is used to monitor changes in CHK2 protein levels, providing a tool for tumor diagnosis and targeted drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063372A_ABST
    Figure CN123063372A_ABST
Patent Text Reader

Abstract

This invention discloses a CHK2 K472 site-modified polypeptide, a specific antibody, and their applications, belonging to the field of polyclonal antibody technology. This invention provides two CHK2 K472 site crotonylation-modified polypeptides, which, when used as antigens to immunize animals, yielded two polyclonal antibodies: Anti-Crotonyl CHK2 (K472)-1415R311 and Anti-Crotonyl CHK2 (K472)-1415R411. The provided polyclonal antibodies have a titer of 1:54,000, differing from the negative unmodified polypeptide by two or more gradients, demonstrating high specificity. The provided polyclonal antibodies can be used to capture novel signal switches regulating CHK2 function, specifically fish for and track crotonylated CHK2 proteins in complex cellular protein mixtures, and to prepare monitoring agents for monitoring changes in CHK2 K472cr levels under intracellular and extracellular signal stimulation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of polyclonal antibody technology, and in particular to CHK2 K472 site modified peptides, specific antibodies and their applications. Background Technology

[0002] Cell cycle checkpoint kinase 2 (CHK2) plays a central role in sensing DNA damage and maintaining genome stability. When cellular DNA suffers damage such as double-strand breaks (DSBs), CHK2 is activated by phosphorylation by upstream ATM kinases. Activated CHK2 acts as a signal amplifier, phosphorylating a series of downstream substrates to execute various important cell fate decisions. It arrests the cell cycle by phosphorylating and inhibiting phosphatases such as CDC25C, causing the cell cycle to stop at the G1 / S or G2 / M checkpoint, thus buying time for DNA repair; it initiates DNA repair by phosphorylating proteins such as BRCA1 and BRCA2, promoting precise repair pathways such as homologous recombination repair (HR); and it induces apoptosis by phosphorylating and stabilizing the tumor suppressor p53 or activating the transcription factor E2F1, thus initiating the apoptosis program when DNA damage cannot be repaired.

[0003] The preparation of CHK2-specific antibodies can provide a direct tool for capturing novel signal switches that regulate CHK2 function, elucidating DNA damage repair, exploring new mechanisms of tumor development and progression, and developing targeted drugs. Summary of the Invention

[0004] The purpose of this invention is to provide a CHK2 K472 site-modified polypeptide, a specific antibody, and their applications. The provided polyclonal antibody is a CHK2 K472 site-specific antibody that can specifically recognize K472 crotonylation. It can serve as a novel signal switch for capturing and regulating CHK2 function, elucidating DNA damage repair, exploring new mechanisms of tumor development, and a direct tool for targeted drug development.

[0005] To achieve the above objectives, the present invention provides two CHK2 K472 site modified polypeptides, wherein the modified polypeptides are crotonylated modified polypeptides and the amino acid sequences are shown in SEQ ID NO.1 and SEQ ID NO.2.

[0006] Polyclonal antibodies were obtained by immunizing animals with the above two CHK2 K472 site modified peptides as antigens, including New Zealand rabbits.

[0007] The method for preparing polyclonal antibodies as described above includes the following steps: conjugating CHK2 modified peptides with carrier proteins to obtain complete antigens, immunizing animals after complete mixing with adjuvants, collecting blood from immunized animals to prepare antiserum, and separating and purifying polyclonal antibodies from the antiserum.

[0008] Preferably, the carrier protein is KLH, and the C-terminus of the modified polypeptide is coupled to KLH.

[0009] Preferably, the adjuvant is Freund's adjuvant, and the volume ratio of complete antigen to adjuvant is 1:1.

[0010] Preferably, the purification is performed using protein A affinity chromatography. The column is washed with PBS buffer and then eluted with glycine buffer. The collected eluent is loaded onto a equilibrated antigen-peptide affinity chromatography column to enrich the target antibody. The obtained target antibody is then loaded onto an unmodified affinity chromatography column and the eluent is collected to obtain the purified polyclonal antibody.

[0011] The application of polyclonal antibodies as described above in the preparation of novel targeted drugs that target malignant tumors.

[0012] The application of the polyclonal antibody as described above in the preparation of a CHK2 K472cr level monitoring agent, wherein the monitoring agent includes the polyclonal antibody; the monitoring agent is used to monitor changes in CHK2 K472cr levels under intracellular and extracellular signal stimulation.

[0013] A reagent for detecting CHK2 protein levels, the reagent comprising the aforementioned polyclonal antibody.

[0014] A method for detecting CHK2 protein for non-diagnostic purposes, using the aforementioned polyclonal antibody as the detection antibody to detect the expression level of CHK2 protein.

[0015] Therefore, the CHK2 K472 site modified polypeptide, specific antibody, and their applications provided by this invention have the following specific technical effects: (1) This invention provides two crotonyl-modified polypeptides at the CHK2 K472 site, the amino acid sequences of which are shown in SEQ ID NO.1 and SEQ ID NO.2; two polyclonal antibodies, Anti-Crotonyl CHK2(K472)-1415R311 and Anti-Crotonyl CHK2(K472)-1415R411, were obtained by immunizing animals with these polypeptides as antigens. (2) The two polyclonal antibodies provided by this invention have an ELISA positive (OD450>1.0) antibody dilution greater than 54,000, which is two or more gradients different from the negative unmodified peptide; the positive detection limit of Dot blot reaches 4ng, and it basically does not recognize the negative unmodified peptide; it can recognize endogenous CHK2 (K472) by WB, and the band size is accurate. (3) The polyclonal antibody provided by the present invention can be used to capture novel signal switches that regulate CHK2 function, specifically fish out and track CHK2 protein that has undergone crotonylation modification in complex cellular protein mixtures; it can be used to prepare monitoring agents for monitoring changes in CHK2 K472cr levels under intracellular and extracellular signal stimulation, which can help subsequent proteomics and signal pathway analysis; it provides the possibility for CHK2 crotonylation to be used as a new diagnostic marker or prognostic indicator for tumors, and provides detection reagents for developing new drug targets.

[0016] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0017] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0018] Figure 1 This is the mass spectrum of CHK2 K472cr polypeptide A; Figure 2 This is the mass spectrum of CHK2 K472cr polypeptide B; Figure 3 This is the mass spectrum of an unmodified polypeptide; Figure 4 The results are from Western blot analysis of the endogenous CHK2 (K472) protein in HT-29 cells in serum after immunization. Figure 5 The results are from Western blot analysis of the endogenous CHK2 (K472) protein in 293T cells by serum after immunization. Figure 6 These are the Dot blot results of the purified antibody; Figure 7 This is the result of Western blotting analysis of the purified antibody. Detailed Implementation

[0019] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0020] To make the objectives, technical solutions, and advantages of this application clearer, more thorough, and more complete, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings and embodiments. The following detailed descriptions are all illustrations of embodiments, intended to provide further detailed explanation of the present invention. Unless otherwise specified, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0021] The instruments, equipment, reagents and materials used in the examples were all obtained commercially; the methods and steps not described in detail are all conventional techniques in the field.

[0022] Example 1 The specific steps for preparing the CHK2 polyclonal antibodies Anti-Crotonyl CHK2 (K472)-1415R311 and Anti-Crotonyl CHK2 (K472)-1415R411 are as follows: (1) Two crotonylated modified peptides and one unmodified peptide were designed and synthesized. The two modified peptides were CHK2K472cr peptide A (amino acid sequence as shown in SEQ ID NO.1) and CHK2K472cr peptide B (amino acid sequence as shown in SEQ ID NO.2), and the amino acid sequence of the unmodified peptide was shown in SEQ ID NO.3. The mass spectrometry results were satisfactory, and the mass spectra were as follows: Figures 1-3 As shown.

[0023] SEQ ID NO.1: VVDP-(Crotonyl)K-ARFTTEEAC SEQ ID NO.2: VVVDP-(Crotonyl)K-ARFTTEEALRC SEQ ID NO.3: VVDPKARFTTEEAC (2) The C-terminus of the two modified peptides were coupled with KLH to obtain CHK2K472cr peptide A-KLH and CHK2K472cr peptide B-KLH, respectively, which were used for rabbit immunization.

[0024] (3) Dilute CHK2 K472cr peptide A-KLH, CHK2 K472cr peptide B-KLH, and unmodified peptide with physiological saline, respectively, and then mix with Freund's adjuvant at a volume ratio of 1:1. The antigen and adjuvant are completely mixed to form a stable emulsion. The emulsion is drawn up with a syringe and injected subcutaneously at two points on both shoulders and intramuscularly at two points on both hind legs of healthy New Zealand rabbits (3-4 months old, 2.5±0.2kg), with about 0.1mL injected into each area. Rabbits immunized with CHK2 K472cr peptide A are labeled as R1 and R2, respectively, and rabbits immunized with CHK2 K472cr peptide B are labeled as R3 and R4, respectively.

[0025] Each rabbit was immunized six times on days 1, 7, 14, 21, 28, and 40. Immediately after immunization on day 28, 2 mL of blood was collected, centrifuged, and the supernatant was used for ELISA. Subsequently, 30 mL of blood was collected three times on days 35, 47, and 52. The supernatant from the fourth immunization serum was centrifuged and used for ELISA or Western blotting.

[0026] The ELISA results are shown in Table 1. The titers of the modified peptides recognized by R1, R2, R3, and R4 were all 1:256K (OD>0.5) and above.

[0027] Table 1. Serum ELISA test results

[0028] Western blot analysis was performed on endogenous CHK2 (K472) protein, with HSP60 as a control. The results are as follows: Figures 4-5 As shown, bands of the target protein at approximately 65 kDa were detected by R2, R3, and R4. Based on the combined results of ELISA and WB, serum from two rabbits (R3 and R4) was selected for purification.

[0029] (4) Mix protein A packing material with an equal volume of PBS buffer, stir, remove air bubbles from the packing material by vacuuming, and slowly add it to the protein A affinity column. Avoid column drying during the column filling process. After filling, use 10 times the volume of pre-cooled PBS buffer solution to equilibrate the column.

[0030] The serum from rabbits R3 and R4 was filtered and then loaded onto a pre-equilibrated protein A chromatography column. To detect the binding efficiency between the antiserum and the packing material, the eluent was retained.

[0031] The column was washed with PBS buffer and then eluted with 150 mM glycine-hydrochloric acid buffer. The eluent was collected and the pH was adjusted to 7 with neutralization buffer.

[0032] The crude purified IgG obtained from protein A was loaded onto a pre-equilibrated antigen-peptide affinity chromatography column for specific enrichment of the target antibody. The resulting target antibody was then loaded onto an unmodified affinity chromatography column, and the eluent (FT3) was collected directly to remove non-specific antibody components, yielding the purified antibody. Antibodies purified from the serum of two rabbits (R3 and R4) were labeled Ab3 and Ab4, respectively. After determining the protein content in the eluent, 10% glycerol was added, and the eluent was aliquoted and stored at -20°C.

[0033] The purified antibody was analyzed by ELISA, Dot Blot, and Western blotting.

[0034] ① Antibodies were added to 96-well ELISA plates coated with antigen-modified peptides and control peptides (unmodified peptides) at different dilution ratios for incubation. Then, enzyme-labeled secondary antibody and TMB substrate were applied, and the binding of peptides and antibodies was detected by colorimetric analysis. The ELISA results are shown in Table 2. Ab3 and Ab4 showed recognition capabilities for CHK2 K472cr peptide B at a dilution of no less than 1:54K (OD450>1.0), differing from the negative unmodified peptide by two gradients or more.

[0035] Table 2. ELISA results of purified antibodies

[0036] ② Modified and unmodified peptides at different doses (e.g., 4 ng, 16 ng) were immobilized on a solid membrane, incubated with antibody, followed by the addition of enzyme-labeled secondary antibody and a chemiluminescent substrate (HRP-labeled goat anti-rabbit). The binding of the peptides and antibodies was then detected. Dot blot results are shown below. Figure 6 As shown, Ab3 and Ab4 antibodies showed virtually no binding to the negative unmodified peptides, but exhibited strong binding to the positive peptides (modified peptides CHK2 K472cr peptide A and CHK2 K472cr peptide B), with a positive detection limit of 4 ng.

[0037] ③ The positive antibodies Ab3 and Ab4 from the Dot / ELISA results were analyzed by Western Blot using 293T+SBA (5mM, 24h) (-) (+) / HT-29+Crotonic (10mM, 24h) (-) (+) lysis buffer. The results are as follows: Figure 7 As shown, Ab3 and Ab4 can be detected as bands of approximately 65 kDa in the above lysis buffer, which is acceptable. In summary, this 65 kDa band represents the target protein CHK2 (K472).

[0038] Therefore, this invention provides two crotonyl-modified peptides at the CHK2 K472 site. Using these peptides as antigens, two polyclonal antibodies, Anti-Crotonyl CHK2 (K472)-1415R311 and Anti-Crotonyl CHK2 (K472)-1415R411, were obtained by immunizing animals. The provided polyclonal antibodies have a titer of 1:54,000, which is two or more gradients different from the negative unmodified peptides. The dot blot detection limit reaches 4 ng, indicating high specificity. Endogenous CHK2 (K472) can be identified by Western blotting, with accurate band size. The provided polyclonal antibodies can be used to capture novel signal switches that regulate CHK2 function, specifically fish out and track crotonyl-modified CHK2 proteins in complex cellular protein mixtures, prepare monitoring agents for monitoring changes in CHK2 K472cr levels under intracellular and extracellular signal stimulation, and develop detection reagents for new drug targets.

[0039] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. 2 CHK2 K472 site modified polypeptides, characterized in that: The modified polypeptide is a crotonylated modified polypeptide, and its amino acid sequence is shown in SEQ ID NO.1 and SEQ ID NO.

2.

2. A polyclonal antibody obtained by immunizing animals with the two CHK2 K472 site modified polypeptides as antigens as described in claim 1, characterized in that: The animals mentioned include the New Zealand rabbit.

3. The method for preparing polyclonal antibodies as described in claim 2, characterized in that, The process includes the following steps: conjugating CHK2-modified peptides with carrier proteins to obtain a complete antigen, immunizing animals with a completely mixed adjuvant, collecting blood from immunized animals to prepare antiserum, and separating and purifying polyclonal antibodies from the antiserum.

4. The method for preparing polyclonal antibodies according to claim 3, characterized in that: The carrier protein is KLH, and the C-terminus of the modified polypeptide is coupled to KLH.

5. The method for preparing polyclonal antibodies according to claim 3, characterized in that: The adjuvant is Freund's adjuvant, and the volume ratio of complete antigen to adjuvant is 1:

1.

6. The method for preparing polyclonal antibodies according to claim 3, characterized in that: Purification was performed using protein A affinity chromatography. The column was washed with PBS buffer and then eluted with glycine buffer. The collected eluent was loaded onto a equilibrated antigen-peptide affinity chromatography column to enrich the target antibody. The obtained target antibody was then loaded onto an unmodified affinity chromatography column and the eluent was collected to obtain the purified polyclonal antibody.

7. The application of the polyclonal antibody as described in claim 2 in the preparation of novel targeted drugs, characterized in that: The targeted drug targets malignant tumors.

8. The application of the polyclonal antibody as described in claim 2 in the preparation of a CHK2 K472cr level monitoring formulation, characterized in that: The monitoring formulation includes the polyclonal antibody; the monitoring formulation is used to monitor changes in CHK2 K472cr levels under intracellular and extracellular signal stimulation.

9. A reagent for detecting the expression level of crotonylation at the K472 site of CHK2 protein, characterized in that: The reagent includes the polyclonal antibody as described in claim 2.

10. A method for detecting crotonylated CHK2 protein at the K472 site for non-diagnostic purposes, characterized in that: Using the polyclonal antibody described in claim 2 as the detection antibody, the expression level of crotonylated CHK2 protein at the K472 site was detected.